drugset
drugset / Trial / NCT01232296

A Study of Dovitinib Versus Sorafenib in Adult Patients With Hepatocellular Carcinoma (HCC) as a First Line Treatment

NCT01232296 ↗

Phase 2 Completed 162 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this open-label, randomized, phase II study is to compare the safety and efficacy of dovitinib versus sorafenib as first-line treatment in adult patients with advanced Hepatocellular Carcinoma (HCC). This trial will be opened in countries of the Asia-Pacific region.

Timeline

Start
2011-07
Primary completion
2014-04
Completion
2014-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Dovitinib Small molecule 500 mg Oral
Subject Sorafenib Small molecule 400 mg Oral

Indications

hepatocellular carcinoma